Aromatase inhibitors (AIs) block estrogen synthesis and profoundly suppress serum estrogen levels. When used to treat ER positive breast cancer, it is therefore counterproductive to prescribe systemic estrogen alongside an AI. This evidence concerns the gene CYP19A1 and breast carcinoma.